Show simple item record

dc.contributor.authorJoseph, Lisa A
dc.contributor.authorRoutledge, Jacqueline A
dc.contributor.authorBurns, Meriel P
dc.contributor.authorSwindell, Ric
dc.contributor.authorSykes, Andrew J
dc.contributor.authorSlevin, Nicholas J
dc.contributor.authorDavidson, Susan E
dc.date.accessioned2013-03-15T16:37:56Z
dc.date.available2013-03-15T16:37:56Z
dc.date.issued2013-02-11
dc.identifier.citationValue of the Hospital Anxiety and Depression Scale in the follow up of head and neck cancer patients. 2013:1-10 J Laryngol Otolen_GB
dc.identifier.issn1748-5460
dc.identifier.pmid23398854
dc.identifier.doi10.1017/S0022215113000078
dc.identifier.urihttp://hdl.handle.net/10541/273024
dc.description.abstractBackground: Few studies have prospectively investigated psychological morbidity in UK head and neck cancer patients. This study aimed to explore changes in psychological symptoms over time, and associations with patients' tumour and treatment characteristics, including toxicity. Methods: Two hundred and twenty patients were recruited to complete the Hospital Anxiety and Depression Scale and the Late Effects on Normal Tissue (Subjective, Objective, Management and Analytic) ('LENT-SOMA') questionnaires, both pre- and post-treatment. Results: Anxiety was highest pre-treatment (38 per cent) and depressive symptoms peaked at the end of treatment (44 per cent). Anxiety significantly decreased and depression significantly increased, comparing pre- versus post-treatment responses (p < 0.001). Hospital Anxiety and Depression Scale scores were significantly correlated with toxicity, age and chemotherapy (p < 0.01 for all). Conclusion: This is the first study to analyse the relationship between Hospital Anxiety and Depression Scale scores and toxicity scores in head and neck cancer patients. It lends support for the use of the Hospital Anxiety and Depression Scale and the Late Effects on Normal Tissue (Subjective, Objective, Management and Analytic) questionnaire in routine clinical practice; furthermore, continued surveillance is required at multiple measurement points.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to The Journal of laryngology and otologyen_GB
dc.titleValue of the Hospital Anxiety and Depression Scale in the follow up of head and neck cancer patients.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.en_GB
dc.identifier.journalJournal of Laryngology and Otologyen_GB
html.description.abstractBackground: Few studies have prospectively investigated psychological morbidity in UK head and neck cancer patients. This study aimed to explore changes in psychological symptoms over time, and associations with patients' tumour and treatment characteristics, including toxicity. Methods: Two hundred and twenty patients were recruited to complete the Hospital Anxiety and Depression Scale and the Late Effects on Normal Tissue (Subjective, Objective, Management and Analytic) ('LENT-SOMA') questionnaires, both pre- and post-treatment. Results: Anxiety was highest pre-treatment (38 per cent) and depressive symptoms peaked at the end of treatment (44 per cent). Anxiety significantly decreased and depression significantly increased, comparing pre- versus post-treatment responses (p < 0.001). Hospital Anxiety and Depression Scale scores were significantly correlated with toxicity, age and chemotherapy (p < 0.01 for all). Conclusion: This is the first study to analyse the relationship between Hospital Anxiety and Depression Scale scores and toxicity scores in head and neck cancer patients. It lends support for the use of the Hospital Anxiety and Depression Scale and the Late Effects on Normal Tissue (Subjective, Objective, Management and Analytic) questionnaire in routine clinical practice; furthermore, continued surveillance is required at multiple measurement points.


This item appears in the following Collection(s)

Show simple item record